Donepezil is ineffective in promoting motor and cognitive benefits after controlled cortical impact injury in male rats

Journal of Neurotrauma

Volumn 30, Issue 7, 2013, Pages 557-564

  Shaw, Kaitlyn E ^a   Bondi, Corina O ^a,b   Light, Samuel H ^a   Massimino, Lire A ^a   McAloon, Rose L ^a   Monaco, Christina M ^a   Kline, Anthony E ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AChE inhibitor; behavior; CCI; functional recovery; learning and memory; Morris water maze; TBI

Indexed keywords

DONEPEZIL; SODIUM CHLORIDE;

ARTICLE; COGNITION; CONTROLLED CORTICAL IMPACT INJURY; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FUNCTIONAL STATUS; INJURY SEVERITY; MALE; MAZE TEST; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; NONHUMAN; POSTOPERATIVE PERIOD; RAT; SHAM PROCEDURE; STATISTICAL SIGNIFICANCE; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDANS; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION;

EID: 84876915235     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2012.2782     Document Type: Article

References (73)

1. Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (2003). Report to Congress on Mild Traumatic Brain Injury in the United States: Steps to Prevent a Serious Public Health Problem. Centers for Disease Control and Prevention: Atlanta.
2. Moore, E.L., Terryberry-Spohr, L., and Hope, D.A. (2006). Mild traumatic brain injury and anxiety sequelae: a review of the literature. Brain Inj. 20, 117-132.
3. Selassie, A.W., Zaloshnja, E., Langlois, J.A., Miller, T., Jones, P., and Steiner, C. (2008). Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J. Head Trauma Rehabil. 23, 123-131.
4. Summers, C.R., Ivins, B., and Schwab, K.A. (2009). Traumatic brain injury in the United States: an epidemiologic overview. Mt. Sinai J. Med. 76, 105-110.
5. Bales, J.W., Wagner, A.K., Kline, A.E., and Dixon, C.E. (2009). Persistent cognitive dysfunction after traumatic brain injury: a dopamine hypothesis. Neurosci. Biobehav. Rev. 33, 981-1003.
6. Faul, M., Xu, L., Wald, M.M., and Coronado, V.G. (2010). Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control: Atlanta.
7. Garcia, A.N., Shah, M.A., Dixon, C.E., Wagner, A.K., and Kline, A.E. (2011). Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation. P.M. R. 3, S18-27.
8. Finkelstein E.A., Corso, P.S., Miller, T.R., and Associates (2006). The Incidence and Economic Burden of Injuries in the United States. New York, NY: Oxford University Press.
9. Corrigan, J.D., Selassie, A.W., and Orman, J.A. (2010). The epidemiology of traumatic brain injury. J. Head Trauma Rehabil. 25, 72-80.
10. Horneman, G., and Emanuelson, I. (2009). Cognitive outcome in children and young adults who sustained severe and moderate traumatic brain injury 10 years earlier. Brain Inj. 23, 907-914.
11. Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (1999). Traumatic Brain Injury in the United States-A Report to Congress. Centers for Disease Control and Prevention: Atlanta.
12. Doppenberg, E.M., Choi, S.C., and Bullock, R. (2004). Clinical trials in traumatic brain injury: lessons for the future. J. Neurosurg. Anesthesiol. 16, 87-94.
13. Tenovuo, O. (2006). Cholinergic treatment of traumatic brain injury. Curr. Drug Ther. 187-209.
14. Flanagan, S.R., Cantor, J.B., and Ashman, T.A. (2008). Traumatic brain injury: future assessment tools and treatment prospects. Neuropsychiatr. Dis. Treat. 4, 877-892.
15. Menon, D.K. (2009). Unique challenges in clinical trials in traumatic brain injury. Crit. Care Med. 37, S129-135.
16. Bornstein, M.B. (1946). Presence and action of acetylcholine in experimental brain trauma. J. Neurophysiol. 9, 349-366.
17. Dewar, D., and Graham, D.I. (1996). Depletion of choline acetyltransferase activity but preservation of M1 and M2 muscarinic receptor binding sites in temporal cortex following head injury: a preliminary human postmortem study. J. Neurotrauma 13, 181-187.
18. Murdoch, I., Perry, E.K., Court, J.A., Graham, D.I., and Dewar, D. (1998). Cortical cholinergic dysfunction after human head injury. J. Neurotrauma 15, 295-305.
19. Shao, L., Ciallella, J.R., Yan, H.Q.,Ma, X., Wolfson, B.M.,Marion, D.W., Dekosky, S.T., and Dixon, C.E. (1999). Differential effects of traumatic brain injury on vesicular acetylcholine transporter and M2 muscarinic receptor mRNA and protein in rat. J. Neurotrauma 16, 555-566.
20. Griffin, S.L., van Reekum, R., and Masanic, C. (2003). A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 15, 17-26.
21. Sarter, M., Hasselmo, M.E., Bruno, J.P., and Givens, B. (2005). Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res. Brain Res. Rev. 48, 98-111.
22. Cardenas, D.D., McLean, A., Jr., Farrell-Roberts, L., Baker, L., Brooke, M., and Haselkorn, J. (1994). Oral physostigmine and impaired memory in adults with brain injury. Brain Inj. 8, 579-587.
23. Gorman, L.K., Fu, K., Hovda, D.A., Murray, M., and Traystman, R.J. (1996). Effects of traumatic brain injury on the cholinergic system in the rat. J. Neurotrauma 13, 457-463.
24. Arciniegas, D., Adler, L., Topkoff, J., Cawthra, E., Filley, C.M., and Reite, M. (1999). Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Brain Inj. 13, 1-13.
25. Dixon, C.E., Bao, J., Long, D.A., and Hayes, R.L. (1996). Reduced evoked release of acetylcholine in the rodent hippocampus following traumatic brain injury. Pharmacol. Biochem. Behav. 53, 679-686.
26. Dixon, C.E., Ma, X., and Marion, D.W. (1997). Reduced evoked release of acetylcholine in the rodent neocortex following traumatic brain injury. Brain Res. 749, 127-130.
27. Ciallella, J.R., Yan, H.Q., Ma, X., Wolfson, B.M., Marion, D.W., DeKosky, S.T., and Dixon, C.E. (1998). Chronic effects of traumatic brain injury on hippocampal vesicular acetylcholine transporter and M2 muscarinic receptor protein in rats. Exp. Neurol. 152, 11-19.
28. Murdoch, I., Nicoll, J.A., Graham, D.I., and Dewar, D. (2002). Nucleus basalis of Meynert pathology in the human brain after fatal head injury. J. Neurotrauma 19, 279-284.
29. Salmond, C.H., Chatfield, D.A., Menon, D.K., Pickard, J.D., and Sahakian, B.J. (2005). Cognitive sequelae of head injury: involvement of basal forebrain and associated structures. Brain 128, 189-200.
30. Holschneider, D.P., Guo, Y., Roch, M., Norman, K.M., and Scremin, O.U. (2011). Acetylcholinesterase inhibition and locomotor function aftermotor-sensory cortex impact injury. J. Neurotrauma 28, 1909-1919.
31. Scremin, O.U., Norman, K.M., Roch, M., Holschneider, D.P., and Scremin, A.M. (2012). Acetylcholinesterase inhibition interacts with training to reverse spatial learning deficits after cortical impact injury. J. Neurotrauma 29, 2457-2464.
32. Hernandez, C.M., Gearhart, D.A., Parikh, V., Hohnadel, E.J., Davis, L.W., Middlemore, M.L., Warsi, S.P., Waller, J.L., and Terry, A.V., Jr. (2006). Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J. Pharmacol. Exp. Ther. 316, 679-694.
33. Bontempi, B., Whelan, K.T., Risbrough, V.B., Lloyd, G.K., and Menzaghi, F. (2003). Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 28, 1235-1246.
34. Taverni, J.P., Seliger, G., and Lichtman, S.W. (1998). Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 12, 77-80.
35. Cheng, J.P., Aslam, H.A., Hoffman, A.N., Zafonte, R.D., and Kline, A.E. (2007). The neurobehavioral benefit conferred by a single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window. Neurosci. Lett. 416, 165-168.
36. Cheng, J.P., Hoffman, A.N., Zafonte, R.D., and Kline, A.E. (2008). A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning. Behav. Brain Res. 194, 79-85.
37. Cheng, J.P., Shaw, K.E., Monaco, C.M., Hoffman, A.N., Sozda, C.N., Olsen, A.S., and Kline, A.E. (2012). A relatively brief exposure to environmental enrichment after experimental traumatic brain injury confers long-term cognitive benefits. J. Neurotrauma 29, 2684-2688.
38. Kline, A.E., Yu, J., Massucci, J.L., Zafonte, R.D., and Dixon, C.E. (2002). Protective effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n- propylamino)tetralin against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats. Neurosci. Lett. 333, 179-182.
39. Kline, A.E., Wagner, A.K., Westergom, B.P., Malena, R.R., Zafonte, R.D., Olsen, A.S., Sozda, C.N., Luthra, P., Panda, M., Cheng, J.P., and Aslam, H.A. (2007). Acute treatment with the 5-HT(1A) receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma. Behav. Brain Res. 177, 186-194.
40. Kline, A.E., McAloon, R.L., Henderson, K.A., Bansal, U.K., Ganti, B.M., Ahmed, R.H., Gibbs, R.B., and Sozda, C.N. (2010). Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury. J. Neurotrauma 27, 2021-2032.
41. Yelleswarapu, N.K., Tay, J.K., Fryer, W.M., Shah, M.A., Garcia, A.N., Cheng, J.P., and Kline, A.E. (2012). Elucidating the role of 5-HT(1A) and 5-HT(7) receptors on 8-OH-DPAT-induced behavioral recovery after experimental traumatic brain injury. Neurosci. Lett. 515, 153-156.
42. Wise, L.E., Iredale, P.A., Stokes, R.J., and Lichtman, A.H. (2007). Combination of rimonabant and donepezil prolongs spatial memory duration. Neuropsychopharmacology 32, 1805-1812.
43. Haug, K.H., Bogen, I.L., Osmundsen, H., Walaas, I., and Fonnum, F. (2005). Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil. Neurochem. Res. 30, 1511-1520.
44. Kline, A.E., Massucci, J.L., Dixon, C.E., Zafonte, R.D., and Bolinger, B.D. (2004). The therapeutic efficacy conferred by the 5-HT(1A) receptor agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) after experimental traumatic brain injury is not mediated by concomitant hypothermia. J. Neurotrauma 21, 175-185.
45. Kline, A.E., Olsen, A.S., Sozda, C.N., Hoffman, A.N., and Cheng, J.P. (2012). Evaluation of a combined treatment paradigm consisting of environmental enrichment and the 5-HT(1A) receptor agonist buspirone after experimental traumatic brain injury. J. Neurotrauma 29, 1960-1969.
46. Feeney, D.M., Gonzalez, A., and Law, W.A. (1982). Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 217, 855-857.
47. Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47-60.
48. Hamm, R.J., Dixon, C.E., Gbadebo, D.M., Singha, A.K., Jenkins, L.W., Lyeth, B.G., and Hayes, R.L. (1992). Cognitive deficits following traumatic brain injury produced by controlled cortical impact. J. Neurotrauma 9, 11-20.
49. Olsen, A.S., Sozda, C.N., Cheng, J.P., Hoffman, A.N., and Kline, A.E. (2012). Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT(1A)-receptor agonist buspirone. J. Neurotrauma 29, 1898-1907.
50. Seltzer, B. (2005). Donepezil: a review. Expert Opin. Drug Metab. Toxicol. 1, 527-536.
51. Liang, Y.Q., and Tang, X.C. (2004). Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci. Lett. 361, 56-59.
52. Chen, Z., Xu, A.J., Li, R., and Wei, E.Q. (2002). Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147. Acta Pharmacol. Sin. 23, 355-360.
53. Lindner, M.D., Hogan, J.B., Hodges, D.B., Jr., Orie, A.F., Chen, P., Corsa, J.A., Leet, J.E., Gillman, K.W., Rose, G.M., Jones, K.M., and Gribkoff, V.K. (2006). Donepezil primarily attenuates scopolamineinduced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology (Berl) 188, 629-640.
54. Su, D., Zhao, Y., Wang, B., Xu, H., Li, W., Chen, J., and Wang, X. (2011). Isoflurane-induced spatial memory impairment in mice is prevented by the acetylcholinesterase inhibitor donepezil. PLoS One 6, e27632.
55. Pike, B.R., and Hamm, R.J. (1997). Chronic administration of a partial muscarinic M1 receptor agonist attenuates decreases in forebrain choline acetyltransferase immunoreactivity following experimental brain trauma. Exp. Neurol. 147, 55-65.
56. Rezvani, A.H., Cauley, M.C., Johnson, E.C., Gatto, G.J., and Levin, E.D. (2012). Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats. Psychopharmacology (Berl) 223, 251-258.
57. Shaw, K.P., Aracava, Y., Akaike, A., Daly, J.W., Rickett, D.L., and Albuquerque, E.X. (1985). The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol. Pharmacol. 28, 527-538.
58. Besheer, J., and Bevins, R.A. (2004). Acetylcholine: II. Nicotinic receptors, in: From Messenger to Molecules: Memories are Made of These. G. Riedel, and B. Platt, (eds.). Landes Bioscience: Austin, pps. 113-124.
59. Pike, B.R., Hamm, R.J., Temple, M.D., Buck, D.L., and Lyeth, B.G. (1997). Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury. J. Neurotrauma 14, 897-905.
60. DeAngelis, M.M., Hayes, R.L., and Lyeth, B.G. (1994). Traumatic brain injury causes a decrease in M2 muscarinic cholinergic receptor binding in the rat brain. Brain Res. 653, 39-44.
61. Pike, B.R., and Hamm, R.J. (1995). Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats. Brain Res. 686, 37-43.
62. Albin, R.L., Young, A.B., and Penney, J.B. (1988). Tetrahydro-9- aminoacridine (THA) interacts with the phencyclidine (PCP) receptor site. Neurosci. Lett. 88, 303-307.
63. Hamm, R.J., Pike, B.R., O'Dell, D.M., and Lyeth, B.G. (1994). Traumatic brain injury enhances the amnesic effect of an NMDA antagonist in rats. J. Neurosurg. 81, 267-271.
64. Creeley, C.E., Wozniak, D.F., Nardi, A., Farber, N.B., and Olney, J.W. (2008). Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol. Aging 29, 153-167.
65. Maurice, T., Meunier, J., Feng, B., Ieni, J., and Monaghan, D.T. (2006). Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J. Pharmacol. Exp. Ther. 317, 606-614.
66. McCarthy, A.D., Owens, I.J., Bansal, A.T., McTighe, S.M., Bussey, T.J., and Saksida, L.M. (2011). FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease. Pharmacol. Biochem. Behav. 98, 76-80.
67. Li, D.Q., Zhou, Y.P., and Yang, H. (2012). Donepezil combined with natural hirudin improves the clinical symptoms of patients with mildto-moderate Alzheimer's disease: a 20-week open-label pilot study. Int. J. Med. Sci. 9, 248-255.
68. Walker, W., Seel, R., Gibellato, M., Lew, H., Cornis-Pop, M., Jena, T., and Silver, T. (2004). The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Inj. 18, 739-750.
69. Khateb, A., Ammann, J., Annoni, J.M., and Diserens, K. (2005). Cognition-enhancing effects of donepezil in traumatic brain injury. Eur. Neurol. 54, 39-45.
70. Zhang, L., Plotkin, R.C., Wang, G., Sandel, M.E., and Lee, S. (2004). Cholinergic augmentation with donepezil enhances recovery in shortterm memory and sustained attention after traumatic brain injury. Arch. Phys. Med. Rehabil. 85, 1050-1055.
71. Tenovuo, O. (2005). Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 61-67.
72. Morey, C.E., Cilo, M., Berry, J., and Cusick, C. (2003). The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. Brain Inj. 17, 809-815.
73. Courtney, C., Farrell, D., Gray, R., Hills, R., Lynch, L., Sellwood, E., Edwards, S., Hardyman, W., Raftery, J., Crome, P., Lendon, C., Shaw, H., Bentham, P., and AD2000 Collaborative Group (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363, 2105-2115.